Inhaled Cannabis for Treatment of PTSD
ConditionPost Traumatic Stress Disorder PTSD
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMultidisciplinary Association for Psychedelic Studies
About this trial
The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.
Eligibility criteria
Qualifiers
Be at least 18 years old.
Be a veteran with PTSD lasting 6 months in duration.
Meet DSM-5 criteria for PTSD with symptoms
Have PTSD of at least moderate severity at the time of screening.
Disqualifiers
Are pregnant, nursing, or are a person able to become pregnant who are not practicing an effective means of birth control.
Have current major depressive disorder with primary psychotic features
Have current or past DSM-5 diagnosis of eating disorder with active purging, personality disorders, primary psychotic disorder, or bipolar affective disorder type 1
Have current or past DSM-5 diagnosis of dissociative identity disorder, positive family history (first degree relative) of psychotic disorder or bipolar affective disorder type 1
Trial design
Treatments tested in this trial
- High THC Cannabis
- Placebo cannabis
Treatment groups
320 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Multidisciplinary Association for Psychedelic Studies
Lead sponsor
Changemark Research + Evaluation Ltd.
Collaborator
Source ClinicalTrials.gov